Basal RYANODINE (cas 15662-33-6) receptor activity suppresses autophagic flux
-
Add time:09/07/2019 Source:sciencedirect.com
The inositol 1,4,5-trisphosphate receptors (IP3Rs) and intracellular Ca2+ signaling are critically involved in regulating different steps of autophagy, a lysosomal degradation pathway. The RYANODINE (cas 15662-33-6) receptors (RyR), intracellular Ca2+-release channels mainly expressed in excitable cell types including muscle and neurons, have however not yet been extensively studied in relation to autophagy. Yet, aberrant expression and excessive activity of RyRs in these tissues has been implicated in the onset of several diseases including Alzheimer’s disease, where impaired autophagy regulation contributes to the pathology. In this study, we determined whether pharmacological RyR inhibition could modulate autophagic flux in ectopic RyR-expressing models, like HEK293 cells and in cell types that endogenously express RyRs, like C2C12 myoblasts and primary hippocampal neurons. Importantly, RyR3 overexpression in HEK293 cells impaired the autophagic flux. Conversely, in all cell models tested, pharmacological inhibition of endogenous or ectopically expressed RyRs, using dantrolene or ryanodine, augmented autophagic flux by increasing lysosomal turn-over (number of autophagosomes and autolysosomes measured as mCherry-LC3 punctae/cell increased from 70.37 ± 7.81 in control HEK RyR3 cells to 111.18 ± 7.72 and 98.14 ± 7.31 after dantrolene and ryanodine treatments, respectively). Moreover, in differentiated C2C12 cells, transmission electron microscopy demonstrated that dantrolene treatment decreased the number of early autophagic vacuoles from 5.9 ± 2.97 to 1.8 ± 1.03 per cellular cross section. The modulation of the autophagic flux could be linked to the functional inhibition of RyR channels as both RyR inhibitors efficiently diminished the number of cells showing spontaneous RyR3 activity in the HEK293 cell model (from 41.14% ± 2.12 in control cells to 18.70% ± 2.25 and 9.74% ± 2.67 after dantrolene and ryanodine treatments, respectively). In conclusion, basal RyR-mediated Ca2+-release events suppress autophagic flux at the level of the lysosomes.
We also recommend Trading Suppliers and Manufacturers of RYANODINE (cas 15662-33-6). Pls Click Website Link as below: cas 15662-33-6 suppliers
Prev:RYANODINE (cas 15662-33-6) receptor dysfunction in human disorders☆
Next:ArticleMapping RYANODINE (cas 15662-33-6) Binding Sites in the Pore Cavity of RYANODINE (cas 15662-33-6) Receptors) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Molecules in focusRYANODINE (cas 15662-33-6) receptor Ca2+ release channel post-translational modification: Central player in cardiac and skeletal muscle disease09/10/2019
- A de novo heterozygous cardiac RYANODINE (cas 15662-33-6) receptor gene (RYR2) mutation in a catecholaminergic polymorphic ventricular tachycardia patient09/09/2019
- ArticleMapping RYANODINE (cas 15662-33-6) Binding Sites in the Pore Cavity of RYANODINE (cas 15662-33-6) Receptors09/08/2019
- RYANODINE (cas 15662-33-6) receptor dysfunction in human disorders☆09/06/2019
- Research paperStructural development of a type-1 RYANODINE (cas 15662-33-6) receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay09/05/2019
- Synthesis, insecticidal evaluation and mode of action of novel anthranilic diamide derivatives containing sulfur moiety as potential RYANODINE (cas 15662-33-6) receptor activators09/04/2019
- Interaction of the Homer1 EVH1 domain and skeletal muscle RYANODINE (cas 15662-33-6) receptor09/03/2019
- ArticleInfluence of Lipid Mimetics on Gating of RYANODINE (cas 15662-33-6) Receptor09/02/2019
- A novel target for the promotion of dermal wound healing: RYANODINE (cas 15662-33-6) receptors09/01/2019